Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
BMC Neurology
Published in: BMC Neurology 1/2016

Open Access 01-12-2016 | Commentary

Multiple sclerosis: clinical profiling and data collection as prerequisite for personalized medicine approach

Authors: Tjalf Ziemssen, Raimar Kern, Katja Thomas

Published in: BMC Neurology | Issue 1/2016

Login to get access

Abstract

Multiple sclerosis (MS) is a highly heterogeneous disease as it can present inter-individually as well as intra-individually, with different disease phenotypes emerging during different stages in the long-term disease course. In addition to advanced immunological, genetic and magnetic resonance imaging (MRI) profiling of the patient, the clinical profiling of MS patients needs to be widely implemented in clinical practice and improved by including a greater range of relevant parameters as patient-reported outcomes. It is crucial to implement a high standard of clinical characterization of individual patients as this is key to effective long-term observation and evaluation.
To generate reliable real-world data, individual clinical data should be collected in specific MS registries and/or using intelligent software instruments as the Multiple Sclerosis Documentation System 3D. Computational analysis of biological processes will play a key role in the transition to personalized MS treatment. Major breakthroughs in the areas of bioinformatics and computational systems biology will be required to process this complex information to enable improved personalization of treatment for MS patients.
Literature
1.
2.
Freedman MS. Improving long-term follow-up studies of immunomodulatory therapies. Neurology. 2011;76:S35–8.CrossRefPubMed
3.
Daumer M, Neuhaus A, Herbert J, Ebers G. Prognosis of the individual course of disease: the elements of time, heterogeneity and precision. J Neurol Sci. 2009;287 Suppl 1:S50–5.CrossRefPubMed
4.
5.
Ziemssen T, Derfuss T, de Stefano N, Giovannoni G, Palavra F, Tomic D, et al. Optimizing treatment success in multiple sclerosis. J Neurol. 2016;263:1053–65.CrossRefPubMed
6.
Ziemssen T, de Stefano N, Pia Sormani M, Van Wijmeersch B, Wiendl H, Kieseier BC. Optimizing therapy early in multiple sclerosis: An evidence-based view. Multiple Sclerosis and Related Disorders. 2015;4:460–9.
7.
Cross AH, Wingerchuk DM, Weinshenker BG. Active and progressive: A new duality of MS classification. Neurology. 2014;83(3):206–7.
8.
9.
Miller A, Avidan N, Tzunz-Henig N, Glass-Marmor L, Lejbkowicz I, Pinter RY, et al. Translation towards personalized medicine in Multiple Sclerosis. J Neurol Sci. 2008;274:68–75. CrossRefPubMed
10.
Austin C, Kusumoto F. The application of Big Data in medicine: current implications and future directions. J Interv Card Electrophysiol. 2016. in press.
11.
Río J, Comabella M, Montalban X. Predicting responders to therapies for multiple sclerosis. Nat Rev Neurol. 2009;5:553–60.CrossRefPubMed
12.
Ross AP, Halper J, Harris CJ. Assessing relapses and response to relapse treatment in patients with multiple sclerosis: a nursing perspective. Int J MS Care. 2012;14:148–59.CrossRefPubMedPubMedCentral
13.
Ziemssen T, Kempcke R, Eulitz M, Großmann L, Suhrbier A, Thomas K, et al. Multiple sclerosis documentation system (MSDS): moving from documentation to management of MS patients. J Neural Transm. 2013;120 Suppl 1:61–6.CrossRef
14.
Ziemssen T. Multiple sclerosis beyond EDSS: depression and fatigue. J Neurol Sci. 2009;277 Suppl 1:S37–41.CrossRefPubMed
15.
Ford DV, Jones KH, Middleton RM, Lockhart-Jones H, Maramba ID, Noble GJ, et al. The feasibility of collecting information from people with Multiple Sclerosis for the UK MS Register via a web portal: characterising a cohort of people with MS. BMC Med Inform Decis Mak. 2012;12:73.CrossRefPubMedPubMedCentral
16.
Kern R, Haase R, Eisele JC, Thomas K, Ziemssen T. Designing an Electronic Patient Management System for Multiple Sclerosis: Building a Next Generation Multiple Sclerosis Documentation System. Interact J Med Res. 2016;5:e2.CrossRefPubMedPubMedCentral
17.
Cohen YC, Hassin-Baer S, Olmer L, Barishev R, Goldhammer Y, Freedman L, et al. MS-CANE: a computer-aided instrument for neurological evaluation of patients with multiple sclerosis: enhanced reliability of expanded disability status scale (EDSS) assessment. Mult Scler. 2000;6:355–61.CrossRefPubMed
18.
Ebers GC, Heigenhauser L, Daumer M, Lederer C, Noseworthy JH. Disability as an outcome in MS clinical trials. Neurology. 2008;71:624–31.CrossRefPubMed
19.
Gaspari M, Roveda G, Scandellari C, Stecchi S. An expert system for the evaluation of EDSS in multiple sclerosis. Artif Intell Med. 2002;25:187–210.CrossRefPubMed
20.
Hatzakis MJ, Allen C, Haselkorn M, Anderson SM, Nichol P, Lai C, et al. Use of medical informatics for management of multiple sclerosis using a chronic-care model. JRRD. 2006;43:1.CrossRef
21.
Rauch A, Cieza A, Stucki G. How to apply the International Classification of Functioning, Disability and Health (ICF) for rehabilitation management in clinical practice. Eur J Phys Rehabil Med. 2008;44:329–42.PubMed
22.
Kamal AH, Bull J, Ritchie CS, Kutner JS, Hanson LC, Friedman F, et al. Adherence to Measuring What Matters Measures Using Point-of-Care Data Collection Across Diverse Clinical Settings. J Pain Symptom Manage. 2016;51:497–503.CrossRefPubMed
23.
Jokubaitis VG, Spelman T, Lechner-Scott J, Barnett M, Shaw C, Vucic S, et al. The Australian Multiple Sclerosis (MS) Immunotherapy Study: A Prospective Multicentre Study of Drug Utilisation Using the MSBase Platform. PLoS ONE. 2013;8:e59694.CrossRefPubMedPubMedCentral
24.
Myhr KM, Grytten N, Torkildsen Ø, Wergeland S, Bö L, Aarseth JH. The Norwegian Multiple Sclerosis Registry and Biobank. Acta Neurol Scand. 2015;132:24–8.CrossRefPubMed
25.
26.
27.
Weathers AL, Esper GJ. How to select and implement an electronic health record in a neurology practice. Neurology: Clinical Practice. 2013;3:141–8.
28.
Osborne LA, Middleton RM, Jones KH, Ford DV, Noble JG. Desirability and expectations of the UK MS Register: views of people with MS. Int J Med Inform. 2013;82:1104–10.CrossRefPubMed
29.
Chitnis T, Tardieu M, Amato MP, Banwell B, Bar-Or A, Ghezzi A, et al. International Pediatric MS Study Group Clinical Trials Summit: meeting report. Neurology. 80(12):1161–8.
30.
Butzkueven H, Chapman J, Cristiano E, Grand’Maison F, Hoffmann M, Izquierdo G, et al. MSBase: an international, online registry and platform for collaborative outcomes research in multiple sclerosis. Mult Scler. 2006;12:769–74.CrossRefPubMed
31.
32.
de Stefano N, Stromillo ML, Rossi F, Battaglini M, Giorgio A, Portaccio E, et al. Improving the characterization of radiologically isolated syndrome suggestive of multiple sclerosis. PLoS One. 2011;6:e19452.CrossRefPubMedPubMedCentral
33.
Balcer LJ, Frohman EM. Evaluating loss of visual function in multiple sclerosis as measured by low-contrast letter acuity. Neurology. 2010;74 Suppl 3:S16–23.CrossRefPubMed
34.
Stangel M, Penner IK, Kallmann BA, Lukas C, Kieseier BC. Towards the implementation of “no evidence of disease activity” in multiple sclerosis treatment: the multiple sclerosis decision model. Ther Adv Neurol Disord. 2015;8:3–13.CrossRefPubMedPubMedCentral
35.
Rudick RA, Miller D, Bethoux F, Rao SM, Lee J-C, Stough D, et al. The Multiple Sclerosis Performance Test (MSPT): an iPad-based disability assessment tool. J Vis Exp. 2014;(88):e51318.
36.
Ziemssen T, Kern R, Cornelissen C. Study design of PANGAEA 2.0, a non-interventional study on RRMS patients to be changed to fingolimod. BMC Neurol. 2016, in press.
37.
Sonder JM, Balk LJ, van der Linden FA, Bosma LV, Polman CH, Uitdehaag BM. Toward the use of proxy reports for estimating long-term patient-reported outcomes in multiple sclerosis. Mult Scler. 2015;21(14):1865–71.
38.
Haase R, Kullmann J, Ziemssen T. Therapy satisfaction and adherence in patients with relapsing–remitting multiple sclerosis: the THEPA-MS survey. Ther Adv Neurol Disord. 2016;9(4):250–63.
39.
Doward LC, McKenna SP, Meads DM, Twiss J, Eckert BJ. The development of patient-reported outcome indices for multiple sclerosis (PRIMUS). Mult Scler. 2009;15:1092–102.CrossRefPubMed
40.
Phillips G, Guo S, Bender R, Havrdova E, Proskorovsky I, Vollmer T. Assessing the impact of multiple sclerosis disease activity and daclizumab HYP treatment on patient-reported outcomes_ Results from the SELECT trial. Multiple Sclerosis and Related Disorders. 2016;6:66–72.
41.
Coyle PK, Cohen BA, Leist T, Markowitz C, Oleen-Burkey M, Schwartz M, et al. Therapy optimization in multiple sclerosis: a prospective observational study of therapy compliance and outcomes. BMC Neurol. 2014;14:49.CrossRefPubMedPubMedCentral
42.
Lublin FD, Reingold SC, Cohen JA, Cutter GR, Sørensen PS, Thompson AJ, et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology. 2014;83:278–86.CrossRefPubMedPubMedCentral
43.
Jensen RE, Rothrock NE, DeWitt EM, Spiegel B, Tucker CA, Crane HM, et al. The role of technical advances in the adoption and integration of patient-reported outcomes in clinical care. Med Care. 2015;53:153–9.CrossRefPubMedPubMedCentral
44.
Haase R, Schultheiss T, Kempcke R, Thomas K, Ziemssen T. Use and acceptance of electronic communication by patients with multiple sclerosis: a multicenter questionnaire study. J Med Internet Res. 2012;14:e135.CrossRefPubMedPubMedCentral
45.
Haase R, Schultheiß T, Kempcke R, Thomas K, Ziemssen T. Modern communication technology skills of patients with multiple sclerosis. Mult Scler. 2013;19:1240–1.CrossRefPubMed
46.
Coons SJ, Eremenco S, Lundy JJ, O’Donohoe P, O’Gorman H, Malizia W. Capturing Patient-Reported Outcome (PRO) Data Electronically: The Past, Present, and Promise of ePRO Measurement in Clinical Trials. Patient. 2015;8:301–9.CrossRefPubMed
47.
Salaffi F, Gasparini S, Grassi W. The use of computer touch-screen technology for the collection of patient-reported outcome data in rheumatoid arthritis: comparison with standardized paper questionnaires. Clin Exp Rheumatol. 2009;27:459–68.PubMed
48.
Griffiths-Jones W, Norton MR, Fern ED, Williams DH. The Equivalence of Remote Electronic and Paper Patient Reported Outcome (PRO) Collection. J Arthroplasty. 2014;29:2136–9.CrossRefPubMed
49.
Rose M, Bjorner JB, Fischer F, Anatchkova M, Gandek B, Klapp BF, et al. Computerized adaptive testing--ready for ambulatory monitoring? Psychosom Med. 2012;74:338–48.CrossRefPubMed
50.
51.
Cook SD, Dhib-Jalbut S, Dowling P, Durelli L, Ford C, Giovannoni G, et al. Use of Magnetic Resonance Imaging as Well as Clinical Disease Activity in the Clinical Classification of Multiple Sclerosis and Assessment of Its Course: A Report from an International CMSC Consensus Conference, March 5–7, 2010. Int J MS Care. 2012;14:105–14.CrossRefPubMedPubMedCentral
52.
Disanto G, Benkert P, Lorscheider J, Mueller S, Vehoff J, Zecca C, et al. The Swiss Multiple Sclerosis Cohort-Study (SMSC): A Prospective Swiss Wide Investigation of Key Phases in Disease Evolution and New Treatment Options. PLoS One. 2016;11:e0152347–13.CrossRefPubMedPubMedCentral
53.
Katsavos S, Anagnostouli M. Biomarkers in Multiple Sclerosis: An Up-to-Date Overview. Multiple Sclerosis International. 2013;2013:1–20.CrossRef
54.
55.
Hurwitz BJ. Registry studies of long-term multiple sclerosis outcomes: description of key registries. Neurology. 2011;76:S3–6.CrossRefPubMed
56.
Rothenbacher D, Capkun G, Uenal H, Tumani H, Geissbühler Y, Tilson H. New opportunities of real-world data from clinical routine settings in life-cycle management of drugs: example of an integrative approach in multiple sclerosis. Curr Med Res Opin. 2015;31:953–65.CrossRefPubMed
57.
Dorsey ER, Venuto C, Venkataraman V, Harris DA, Kieburtz K. Novel Methods and Technologies for 21st-Century Clinical Trials. JAMA Neurol. 2015;72(5):582–8.
58.
Tremlett H, Paty D, Devonshire V. The natural history of primary progressive MS in British Columbia, Canada. Neurology. 2005;65(12):1919–23.
59.
Vollmer TL, Ni W, Stanton S, Hadjimichael O. The NARCOMS Patient Registry: A Resource for Investigators. Int J MS Care. 1999;1:28–34.CrossRef
60.
Ziemssen T, Gilgun-Sherki Y. Sub-analysis of geographical variations in the 2-year observational COPTIMIZE trial of patients with relapsing-remitting multiple sclerosis converting to glatiramer acetate. BMC Neurol. 2015;15:189.CrossRefPubMedPubMedCentral
61.
Schultheiß T, Kempcke R, Kratzsch F, Eulitz M, Pette M, Reichmann H, et al. [Multiple sclerosis management system 3D : Moving from documentation towards management of patients.]. Nervenarzt. 2012;83:450–7.
62.
Thomas K, Ziemssen T. Management of fingolimod in clinical practice. Clinical Neurology and Neurosurgery. Elsevier. 2013;115 Suppl 1:S60–4.
63.
Ziemssen T, Engelmann U, Jahn S, Leptich A, Kern R, Hassoun L, et al. Rationale, Design, and Methods of a Non-interventional Study to Establish Safety, Effectiveness, Quality of Life, Cognition, Health-Related and Work Capacity Data on Alemtuzumab in Multiple Sclerosis Patients in Germany (TREAT-MS). BMC Neurol. 2016;16:109.
64.
Ziemssen T, Gass A, Würfel J, Bayas A, Tackenberg B, Limmroth V, et al. Design of TRUST, a non-interventional, multicenter, 3-year prospective study investigating an integrated patient management approach in patients with relapsing-remitting multiple sclerosis treated with natalizumab. BMC Neurol. 2016;16:98.
65.
Ziemssen T, Kern R, Cornelissen C. The PANGAEA study design – a prospective, multicenter, non-interventional, long-term study on fingolimod for the treatment of multiple sclerosis in daily practice. BMC Neurol. 2015;15:93.
66.
Rumsfeld JS, Joynt KE, Maddox TM. Big data analytics to improve cardiovascular care: promise and challenges. Nat Rev Cardiol. 2016;13(6):350–9.
67.
Raghupathi W, Raghupathi V. Big data analytics in healthcare: promise and potential. Health Inf Sci Syst. 2013;2:3–3.CrossRef
68.
Völzke H, Schmidt CO, Baumeister SE, Ittermann T, Fung G, Krafczyk-Korth J, et al. Personalized cardiovascular medicine: concepts and methodological considerations. Nat Rev Cardiol. 2013;10:308–16.CrossRefPubMed
69.
Kaminski N, Bar-Joseph Z. A patient-gene model for temporal expression profiles in clinical studies. J Comput Biol. 2007;14:324–38.CrossRefPubMed
Metadata
Title
Multiple sclerosis: clinical profiling and data collection as prerequisite for personalized medicine approach
Authors
Tjalf Ziemssen
Raimar Kern
Katja Thomas
Publication date
01-12-2016
Publisher
BioMed Central
Published in
BMC Neurology / Issue 1/2016
Electronic ISSN: 1471-2377
DOI
https://doi.org/10.1186/s12883-016-0639-7

Other articles of this Issue 1/2016

BMC Neurology 1/2016 Go to the issue

Research article

The role of visual stimuli on standing posture in children with bilateral cerebral palsy

Case report

Cerebral vasospasm and wernicke encephalopathy secondary to adult cyclic vomiting syndrome: the role of magnesium

Research article

Diffusion tensor imaging in acute-to-subacute traumatic brain injury: a longitudinal analysis

Case report

Combined focal myoclonus and dystonia secondary to a cerebellar hemorrhage: a case report

Technical advance

Ultrasound-guided botulinum toxin A injection in the treatment of belly dancer’s dyskinesia

Case report

Myasthenic symptoms in anti-low-density lipoprotein receptor-related protein 4 antibody-seropositive amyotrophic lateral sclerosis: two case reports